Companies: 10,795·Total market cap: $144.5T
Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc.

HRMYNASDAQHealthcare● Active
$32.39
+$0.19(+0.59%)
Market Cap$1.9B
P/E Ratio
52W High$40.87
52W Low$25.52

Harmony Biosciences Holdings, Inc. (HRMY) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

hrmy · stock forecast · 13 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 13 Wall Street analysts in the past 3 months

SellBuy

Buy

13 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
9
Hold
2
Sell
2
Strong Sell
0
Total: 13 · Buy rate: 69.2%

12-Month Price Target

High

$50.00

Consensus

$43.00

+33.1% upside

Low

$31.00

Median: $45.5 · Last Close: $32.31

The Harmony Biosciences Holdings, Inc. (HRMY) analyst consensus is Buy, based on ratings from 13 Wall Street analysts over the past 3 months. The average 12-month HRMY price target is $43.00, representing +33.1% upside from the current price of $32.31.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $43 (33.1%)

Consensus Target

$43.00

33.1% upside

High Target

$50

54.8%

Low Target

$31

-4.0%

Current Price

$32.31

as of today

Based on analyst price targets, the HRMY stock price prediction for the next 12 months ranges from $31 to $50. The consensus HRMY price forecast of $43.00 implies 33.1% upside from the current price of $32.31.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$33.032.24%

1-day model range: $32.91–$33.15. Peak: $33.15 (+2.24%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$41+26.2%
2028$47+44.3%
2029$50+55.8%
2030$53+62.5%
2031+66.4%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

86%7%7%
12Buy
1Neutral
1Sell
RSI (14)64.8Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · HRMY · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$32.10BUY
MA 10$31.62BUY
MA 20$31.03BUY
MA 50$30.39BUY
MA 100$31.39BUY
MA 200$32.42SELL
Current $HRMY · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$32.14BUY
EMA 10$31.78BUY
EMA 20$31.38BUY
EMA 50$30.97BUY
EMA 100$31.39BUY
EMA 200$32.16BUY
Current $HRMY · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Truist Securities2026-05-08
Maintains
HoldHold
HC Wainwright & Co.2026-02-25
Maintains
BuyBuy
Needham2026-02-25
Maintains
BuyBuy
B of A Securities2026-02-25
Maintains
UnderperformUnderperform
UBS2026-02-25
Maintains
NeutralNeutral
UBS2026-02-11
Downgrade ↓
BuyNeutral
Truist Securities2026-01-08
Maintains
BuyBuy
Mizuho2025-12-01
Maintains
OutperformOutperform
Needham2025-11-24
Maintains
BuyBuy
HC Wainwright & Co.2025-11-24
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Harmony Biosciences Holdings, Inc. (HRMY) stock. Of the recent 109 rating actions, 2 were upgrades and 5 were downgrades. 13 analysts currently cover HRMY.

Analyst Recommendation Trends

Buy ratings101
Hold ratings01↑ +1
Sell ratings00

HRMY analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$1.0B

↓ 19.9% YoY

Revenue Next Year

$1.1B

↑ 13.7% YoY

EPS This Year

$3.43

EPS Next Year

$4.13

↑ 20.4% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast HRMY EPS of $3.43 for the current fiscal year, based on estimates from 7 analysts. The HRMY revenue forecast is $1.0B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The HRMY stock forecast is supported by two independent data sources: analyst consensus ratings from 13 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus HRMY price target is $43.00 (+33.1% upside), with an analyst consensus of Buy.

The HRMY short-term stock prediction for tomorrow is $33.03 (+2.24%). The HRMY stock price prediction for 2027 estimates an average of $41. The HRMY stock prediction for 2030 projects a range of $50–$55.

Harmony Biosciences Holdings, Inc. trades on NASDAQ under the ticker HRMY. The HRMY stock outlook for 2027 is broadly positive, supported by a Buy consensus among 69% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

HRMY forecast · 8 questions

According to 13 Wall Street analysts, the average 12-month HRMY price target is $43.00, with a high forecast of $50.00 and a low of $31.00. The median price target is shown in the chart above when available. This implies +33.1% potential upside from the current price of $32.31.

HRMY price targetWhat is HRMY price targetHRMY analyst price targetHRMY 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.